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Abstract: In the present paper, the extracellular antioxidant activity of N-acetyl-cysteine (NAC) is
explained by considering its ability to regenerate the free form of albumin Cys34 by breaking the
disulfide bond of the cysteinylated form (HSA-Cys). NAC’s capability to regenerate albumin Cys34
(HSA-SH) was studied by MS intact protein analysis in human plasma and in a concentration range of
NAC easily achievable after oral and i.v. administration (5–50 µg/mL). NAC dose-dependently broke
the HSA-Cys bond to form the dimer NAC-Cys thus regenerating Cys34, whose reduced state was
maintained for at least 120 min. Cys was faster in restoring Cys34, according to the reaction constant
determined with the glutathione disulfide (GSSG) reaction, but after 60 min the mixed disulfide
HSA-Cys turned back due to the reaction of the dimer Cys-Cys with Cys34. The explanation for
the different rate exchanges between Cys-Cys and Cys-NAC with Cys34 was given by molecular
modeling studies. Finally, the Cys34 regenerating effect of NAC was related to its ability to improve
the total antioxidant capacity of plasma (TRAP assay). The results well indicate that NAC greatly
increases the plasma antioxidant activity and this effect is not reached by a direct effect but through
the regenerating effect of Cys34.
Keywords: N-acetyl-cysteine; albumin; Cys34; cysteine; antioxidant; plasma
1. Introduction
N-acetylcysteine (NAC), the N-acetyl derivative of the natural amino acid l-cysteine, is a reference
antioxidant compound widely used in in vitro and ex vivo conditions. The antioxidant activity of NAC
is attributed to the thiol group in the thiolate form which acts by scavenging radical and non-radical
oxidants (direct effect) as well to the fact that it acts as a precursor of Cys (through a deacetylation
reaction catalyzed by aminoacylase I) which is the building block of glutathione, GSH (indirect effect),
the main intracellular antioxidant and co-factor of several antioxidant and detoxifying enzymes [1,2].
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A critical insight into the antioxidant property of NAC showed that the direct antioxidant activity
of NAC is not really efficient, in particular when compared to other endogenous thiols such as Cys or
GSH [1]. This is explained by the low acidity of the NAC thiol as a consequence of the amino group
acetylation, making the equilibrium between the antioxidant form (thiolate) and the thiol, largely shift
toward the latter, which is the inactive from. Taking into account the pKa of the thiol group of NAC
(pKa = 9.5), at. pH 7.4, the fraction of the active form is 0.76/100 with respect to the non-active form,
while for Cys (pKa = 8.6) and GSH (pKa = 9.2), it is 6.3/100 and 1.58/100, respectively. On the basis of
these data, we can calculate that at a fixed concentration, the active forms (thiolate) of GSH and Cys
are almost two and eight fold if compared to NAC, respectively. By considering the reaction rates of
the endogenous antioxidants, of the substrates and of NAC toward the main radical and non-radical
oxidants, it can be assumed that NAC acts as a direct antioxidant agent only toward some specific
oxidants and when it is present in a high concentration as when it occurs in in vitro condition.
Based on these premises, we can assume that in in vivo conditions, NAC performs as a cellular
antioxidant by acting as a precursor of GSH but it is still not clear whether and how it works as an
extracellular antioxidant where the content of GSH is quite negligible.
Cys34 of albumin represents the main extracellular antioxidant, characterized by a much higher
antioxidant activity with respect to that of Cys and NAC due to its peculiar acidity (pKa = 8.1)
which is given by a particular microenvironment able to stabilize the thiolate anion [3]. When Cys34
acts as an antioxidant, the corresponding sulfenic acid derivative is formed, which then reacts with
free Cys (the main extracellular low molecular thiol) forming the corresponding mixed disulfide
(cysteinylation reaction) thus preserving the irreversible oxidation of Cys34 to sulfinic and sulfonic acid
derivatives [4]. The cysteinylated form of Cys34 significantly increases in several physio-pathological
oxidative conditions such as aging [5], intrauterine growth restriction [6], cirrhosis [7], and renal
disease [8]. In particular, the physiological content of the cysteinylated form in healthy subjects is
<30%, increasing to ≥40% in oxidative stress conditions [9]. Although it is not yet clear which is the
endogenous pathway deputed to restore Cys34 from the corresponding cysteinylated form, it was
found that NAC is able to restore albumin Cys34 by breaking the cysteinylated form [10]. In this
reaction a not effective direct antioxidant (NAC) is consumed to regenerate the highly effective Cys34,
thus making NAC act as an indirect antioxidant activity.
The beneficial role of Cys34 is not only be related to the extracellular antioxidant but also to
its ability to detoxify several electrophilic and toxic agents [11] such as 4-hydroxynonenal which is
involved in several diseases including metabolic disorders [12–14], and cardiovascular diseases [15].
Considering that the conversion of Cys34 to the cysteinylated form significantly increases in several
oxidative-based diseases, we believe that the ability of NAC to selectively restore Cys34 can have a
pivotal role in maintaining the antioxidant and electrophilic detoxification potential of the extracellular
milieu. Hence NAC is an old molecule which can exert a very promising therapeutic potential through
a mechanism of action which merits deeper investigation.
The aim of this paper is to better characterize the reaction mechanism of NAC as a restoring agent
of Cys34, to compare the reaction rate with respect to that of Cys, and to correlate the thiol-breaking
activity of NAC to its antioxidant activity in human plasma. To reach this goal we firstly examined the
thiol-disulfide breaking activity of NAC in in vitro conditions using GSSG and cysteinylated albumin
as substrates and Cys as reference compound. The ability of NAC to regenerate albumin Cys34 was
then confirmed in human plasma and in a concentration range of NAC easily reachable after oral and
iv administration and using human plasma from healthy donors. Finally, the Cys34 regenerating effect
of NAC was related to its ability to improve the total antioxidant capacity of plasma as measured by the
TRAP assay. The results well indicate that NAC, at a concentration range which can be easily reached
after a single oral or iv administration, greatly increases the plasma antioxidant activity and this effect
is not reached by a direct effect but through a regenerating effect of Cys34 through a thiol-disulfide
breaking mechanism of the cysteinylated albumin. Cys, even if more effective as a thiol-disulfide
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breaking agent, was much less active as antioxidant because it is less effective in maintaining the Cys34
in a free form due to the reaction of cystine with Cys34.
2. Materials and Methods
2.1. Reagents
Formic acid (FA), acetonitrile (CH3CN) and 2,2,3,3,4,4,5,5,5-nonafluoropentanoic acid (NFPA) were
of liquid chromatography-mass spectrometry (LC-MS) grade; N-Acetyl-l-cysteine (NAC), cysteine
(Cys), l-Glutathione oxidized (GSSG), human plasma from human male AB, hydrogen peroxide solution
30% (w/w) in H2O, NaCl, sodium dihydrophosphate, disodium phosphate, 2’,7’-Dichlorofluorescin
diacetate (DCFH-DA), 2,2’-Azobis(2-amidinopropane) dihydrochloride (AAPH) and all other chemicals
were analytical grade and purchased from Sigma-Aldrich (Milan, Italy). Ultrapure water was prepared
by a Milli-Q purification system (Millipore, Bedford, MA, USA).
Plasma samples were obtained from a subset of healthy subjects (controls) from a previously
enrolled population. The study was approved by the Ethical Committee European Institute of Oncology
and Monzino Cardiologic Center (registration number R391/16-CCM406).
2.2. GSSG Disulfides Breaking Activity of NAC and Cys
The rate constants of the thiol-disulfide exchange reaction mediated by NAC and Cys were
measured by using GSSG as disulfide. The time-dependent disappearance of GSSG and the formation
of GSH and of the disulfides (GSH-NAC, GSH-Cys) were determined by LC-ESI-MS/MS. The incubation
mixtures were prepared in 100 mM phosphate buffer at pH 7.4 using the following stoichiometric
ratios between GSSG and the thiol: 1:3–1:2–1:1–1:0.5 and maintaining the GSSG concentration constant
(5 mM). The mixtures were incubated at 37 ◦C under slow stirring (300 RPM) in the Thermomixer
(Eppendorf). Aliquots of the reaction mixtures were taken at different time points (Tmin: T0, T1, T2, T3,
T4, T5, T7.5, T10 and T15), diluted 1:500 with H2O:CH3CN:NFPA 95:5:0.08% v:v:v, filtered using 0.45 µm
Ø13 mm PVDF filters and injected in triplicate in HPLC-MS (10 µL). Analyses were carried out using a
LC-ESI-MS/MS method in Multiple Reaction Monitoring (MRM). The chromatographic separation
was performed on a reversed-phase Phenomenex Kinetex Core-Shell technology-C18 (75 × 2.1 mm,
i.d. 2.6 µm, 100 Å, Milan, Italy) protected by a Phenomenex Kinetex security-guard column, by using
a quaternary pump HPLC system (Surveyor LC system, ThermoQuest, Milan, Italy) equipped with
thermostated compartment for the column kept at 40 ◦C and an autosampler maintained at 8 ◦C,
working at a constant flow rate (200 µL/min). Aliquots of 10 µL of the standard or sample solution
were injected in partial loop mode and analytes were eluted with a 18 min multistep gradient of phase
A (H2O:NFPA, 100:0.08% v/v) and phase B (CH3CN): 0–1 minutes, isocratic of 5% B; 1–3 minutes, from
5% B to 40% B; 3–7 minutes, from 40% B to 70% B; 7–12 minutes, isocratic of 60% B; 12–13 minutes,
from 60% B to 95% B; 1 minute of isocratic 95% B; and then 4 minutes of isocratic 5% B. The MS/MS
analyses were performed with a TSQ Quantum Triple Quadrupole (Thermo Finnigan Italy, Milan,
Italy) mass spectrometer fitted with an electrospray (ESI) interface operating in positive-ion mode,
under the following source parameters: capillary temperature, 275 ◦C; spray voltage 4.5 kV; capillary
voltage, 35 V; and tube lens voltage 102 V. The parameters influencing the transitions were optimized
as follows: argon gas pressure in the collision Q2, 1.0 mTorr; peak full width at half-maximum (fwhm),
0.70 m/z at Q1 and Q3; scan width for all MRM channels, 0.002 m/z; scan time 0.675 s, skimmer offset
10 V.
GSSG analysis was carried out by using the following transitions:
GSSG: m/z 613.00→ 355.00 (collision energy 15 eV)
The calibration curve for GSSG dissolved in H2O/CH3CN/NFPA 95:5:0.08% vol:vol:vol was built
using a concentration range of 0.156 µM–10.000 µM. The peptide LQQCPF was used as internal
standard. Carry-over effects were assessed, with relevant criteria by injecting samples followed by the
calibration standard at the highest concentration. The limit of detection (LOD) was calculated using a
signal to noise ratio (S/N) ≤ 3. Data processing was performed by using Xcalibur 2.0 software.
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The formation of GSH and the adducts GSH-NAC and GSH-Cys disulfides was monitored by
using the following transitions:
GSH: m/z 308.00→ 162.00 + 179.00 + 233.00 (collision energy 15 eV)
GSH-NAC: m/z 469.00→ 340.00 (collision energy 15 eV)
GSH-Cys: m/z 427.10→ 177.00 + 298.00 (collision energy 20 eV)
The standards of the mixed disulfides were prepared from a reaction mixture prepared at a
stoichiometric ratio of 1:3 of GSH and thiol (NAC/Cys) respectively, in 100 mM phosphate buffer at pH
7.4; the reaction mixture was incubated at 37 ◦C for 120 minutes, kept under slow stirring (300 RPM)
using the Thermomixer (Eppendorf). H2O2 at a final concentration of 1 mM was added to catalyze the
formation of the mixed disulfides. Kapp values and the pH-independent rate constants were calculated
according to the method reported by Ferrer-Sueta et al. [16].
2.3. Albumin Cys34-Cys Breaking Activity
2.3.1. Sample Preparation
The time-dependent activity of Cys and NAC in breaking cysteinylated albumin and in regenerating
mercaptoalbumin was determined by using human plasma from Sigma and measuring the relative
content of the two isoforms of albumin by MS intact protein analysis as already described [8]. Aliquots
of 1 mL of plasma were spiked with NAC or Cys at the following final concentrations: 100, 50, 25 µg/mL
(plasma); NAC and Cys stock solutions were previously prepared dissolving both reagents in 100 mM
phosphate buffer at pH 7.4, at a concentration of 1 mg/mL.
The reaction mixtures were incubated at 37 ◦C under slow stirring (400 RPM) in the Thermomixer
(Eppendorf) and at the following reaction time points (Tmin: T0, T1, T2, T3, T5, T10, T20, T30, T60, and
T120) aliquots were withdrawn and diluted 1:40 with a mixture of H2O:CH3CN:FA 70:30:0.1% v:v:v to
stop the reaction. The diluted solutions were transferred into the vials and injected twice (technical
duplicate) into a HPLC-MS system.
2.3.2. Intact Protein Analysis by LC-Mass Spectrometry
The analyses were performed on a reversed-phase Phenomenex LC column Jupiter-C4 (150 × 2 mm,
i.d. 5 µm, 300 Å, Milan, Italy) protected by a Phenomenex security-guard column, by using a Surveyor
system (ThermoFinnigan Italy, Milan, Italy) equipped with thermostated compartment for the column
kept at 40 ◦C and an autosampler at 8 ◦C, working at a constant flow rate (250 µL/min). 10 µL of standard
solutions were injected in partial loop mode and analytes were eluted with a 20min multistep gradient
of phase A H2O:FA (100:0.1% v:v) and organic phase B CH3CN:FA (100:0.1% v:v): 0–2 minutes, isocratic
of 30% B; 2–13 minutes, from 30% B to 50% B; 13–14 minutes, from 50% B to 95% B; 14–17 minutes,
of isocratic 95% B; and then 3 minutes of isocratic 30% B. To prevent potential signal suppression
due to the presence of salts coming from the buffer used for sample preparation, during the first
3 minutes of analysis the eluted mixture was discarded by using the Divert Valve; after the first minute
of analysis the valve was set in a position allowing the elution of the mixture directly in the source.
The eluted species coming from the chromatographic system were analyzed by a triple quadrupole
(TQ) mass spectrometer (Finnigan TSQ Quantum Ultra, ThermoQuest, Milan, Italy) equipped with an
Electrospray Finnigan Ion Max source. MS spectra were acquired under the following instrumental
conditions: positive-ion mode; ESI voltage 3.5 kV, capillary temperature 320 ◦C, capillary voltage 46 V,
Q3 scan range 1200–1500 m/z, Q3 power 0.4 amu, scan time 1 s, Q2 gas pressure 1.5 Torr, skimmer offset
10 V, microscan set to 3. Full instrument control and ESI mass spectra acquisitions were carried out by
Xcalibur software (version 2.0.7, Thermo Fisher Scientific, Rodano, MI, Italy).
2.3.3. Data Elaboration
Mass spectra deconvolution was performed using MagTran software (version 1.02, author:
Zhongqi Zhang, Center for Interdisciplinary Magnetic Resonance, National High Magnetic Field
Laboratory, Florida State University, Tallahassee, Florida, USA), implemented by an algorithm that
allows the calculation of the molecular weight of an analyte based on the m/z values of the single
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multicharged ions recorded. In this way it was possible to monitor the relative content of the following
HSA isoforms: mercaptoalbumin (HSA-SH), cysteinylated HSA (HSA-Cys), glycated HSA (HSA-gly),
and other species not yet identified. Using the spectrum smoothing tool of the MagTran software, and
setting the following parameters: Gaussian Deconvolution Options→Min peak width: 5 Da; Max
peak width: 50 Da; Max iteration: 256; Rho: 0.75; Max no. of gaussians: 5–8, it was possible to calculate
the peak area of each species and the corresponding relative abundance (%) was calculated. The data
relative to the content of mercaptoalbumin and HSA in the cysteinylated form were further elaborated
to calculate, for both species, at each time point, the average values, and standard deviations based on
three injections.
2.4. Measurement of Plasma Antioxidant Capacity
The plasma antioxidant activity in absence and presence of NAC or Cys was evaluated by a
fluorimetric assay based on 2’,7’-dichlorodihydrofluorescein diacetate (DCFH2-DA) as substrate and
AAPH as radical initiator [16].
The DCFH2 was prepared starting from 2’,7’-dichlorodihydrofluorescein diacetate (DCFH2-DA)
by basic hydrolysis: briefly 500 µL of DCFH-DA stock solution (1 mM) was mixed with 2 mL of NaOH
(0.01 N at 4 ◦C) for 20 min while protected from the light. The mixture was then neutralized with 2 mL
of HCl (0.01 N), diluted with phosphate-buffered saline (PBS) to a final concentration of 10 µM and
stored in ice for no longer than 8 h (working solution);
NAC and Cys stock solutions were prepared by dissolving the reagents in 100 mM phosphate buffer
at pH 7.4, at a finale concentration of 1 mg/mL. Plasma samples in absence or presence of NAC or Cys
at different concentrations (25, 50, 100 µg/µL) were incubated at 37 ◦C under slow stirring (400 RPM) in
the Thermomixer (Eppendorf) for 30 minutes. Then 40 µL of the above mentioned samples were spiked
with DCFH2 and AAPH at the final concentration of 10 µM and 10mM, respectively. Samples were
loaded in triplicate on a 96-well plate (BRANDplates pureGrade, BRAND®, 97877 Wertheim, Germany)
and the 2-electron oxidation of DCFH to the highly fluorescent compound 2’,7’-dichlorofluorescein
(DCF) was monitored at 37 ◦C using a multilabel, multitask plate reader (Victor-1420 Multilabel
Counter; Wallac, Turku, Finland) setting the excitation and emission wavelengths at λex 485 nm λem
at 535 nm, respectively.
2.5. Molecular Modeling
The computational analyses were focused on the nucleophilic exchange between the possible
disulfides (Cys-Cys and Cys-NAC) and Cys34 (represented by methanethiol for simplicity) as
simulated by density functional theory (DFT) calculations involving the corresponding anionic
trisulfide intermediates. In detail the conformational profile of the two studied disulfides was explored
by MonteCarlo procedures as implemented in the VEGA suite of programs [17] which generate 1000
conformers by randomly rotating the flexible bonds. The so obtained best structures were optimized
by PM7 semi-empirical method by MOPAC [18] and used to build the corresponding trisulfide
intermediates. All considered molecules were simulated at their ground-state and at gas phase by
density functional theory (DFT) using the Becke three-parameter hybrid function with LYP (Lee,
Yang, Parr) correlation (DFT/B3LYP) and with the 6-31G basis set as implemented by the GAMESS
software [19]. To evaluate the effect of water solvents, the DFT calculations were repeated by applying
the polarizable continuum model (PCM) implicit solvent model.
2.6. Satistical Analysis
One-way ANOVA followed by Dunnett’s multiple comparisons test was performed using
GraphPad Prism version 8.0.0 for Windows (GraphPad Software, San Diego, CA USA).
3. Results
3.1. GSSG Disulfide Breaking Activity of NAC and Cys
The first step was to evaluate the thiol-disulfide breaking activity of NAC and to compare its
reactivity with that of Cys, using GSSG as disulfide. The disulfide breaking activity was monitored by
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measuring the time-dependent consumption of GSSG as determined by LC-ESI-MS in MRM mode.
NAC induced a time-dependent consumption of GSSG reaching the plateau after 10 min of incubation
(data not shown). The GSSG consumption was accompanied by a stoichiometric formation of GSH
and GSH-NAC disulfide (data not shown), thus confirming the disulfide breaking activity according to
the following equilibrium:
GSSG + NAC = GSH + GSH-NAC (1)
The calculated Kapp of NAC was 0.24 M−1 s−1 and that of Cys of 1.99 M−1 s−1. The greater reactivity
of Cys is well explained by considering its higher acidity with respect to NAC (pKa NAC = 9.7 vs. 8.4
of Cys) [20]. The pH-independent rate constant of the thiolate form of Cys and NAC toward GSSG
were calculates as logKNAC = 1.69; logKCys = 1.29, respectively, and this greater nucleophilicity of the
NAC thiolate in respect to that of Cys is due to the reduced acidity of the thiol as already described for
other thiols [21].
3.2. Albumin Cys34-Cys Breaking Activity
The effect of NAC and Cys in breaking the Cys34-Cys disulfide was then determined in human
plasma, provided by Sigma, by measuring the relative content of mercaptoalbumin and of the
corresponding cysteinylated form by intact protein analysis. As shown in Figure 1, the ESI-MS
spectrum of intact HSA shows a multicharged ions profile and the deconvoluted spectrum reports three
main isoforms at 66472, 66592, 66637 Da, relative to the mercaptoalbumin (HSA-SH), the cysteinylated
(HSA-Cys, +120 Da) and the glycated forms (HSA-gly; +165 Da). The relative abundance of the three
isoforms was calculated as follows: HSA-SH: 40%, HSA-Cys: 32%, HSA-gly: 12%.
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Figure 1. ESI-MS spectrum of intact HSA: (a) Multicharged ion profile of HSA. (b) Deconvoluted
spectrum of HSA spectrum showing the mercaptoalbumin (HSA-SH) isoform at 66472 Da, the
cysteinylated form, HSA-Cys, at 66592 Da (+120 Da with respect to HSA-SH) and the glycated form,
HSA-gly, at 66637 Da (+165 Da).
Figure 2 shows the time- and dose-dependent effect of Cys (panel a) and NAC (panel b) in
restoring mercaptoalbumin (upper part of the graph) by reducing the content of the Cys34 form (lower
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part of the graph) through a disulfide breaking of the Cys34-Cys bond. In the graph, the relative
content of both HSA-SH and HSA-Cys at the beginning of the kinetic are set as 0 value.
The strict correlation also in quantitative terms between HSA-SH increase and HSA-Cys
consumption indicates that the disulfide breaking effect of NAC regenerates Cys34 by forming
the mixed disulfide NAC-Cys according to the following equilibrium:
HSA-Cys + NAC = HSA-SH + Cys-NAC (2)
The formation of Cys-NAC/HSA-SH and not of HSA-NAC/Cys-Cys is explained by considering
that the entering nucleophilic moiety (the NAC thiolate) breaks the disulfide bonds and remains linked
to the more basic sulfur atom (Cys) so displacing the more acid thiol function of Cys34.
The quantitative correspondence between the amount of regenerated Cys34 and the consumed
cysteinylated form also well confirms that the disulfide breaking activity of NAC is specific for
Cys34-Cys and does not affect the other disulfides of albumin [22].
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Figure 2. HSA-Cys breaking activity of NAC and Cys: Time- and dose-dependent effect of NAC (a)
and Cys (b) in restoring mercaptoalbumin (upper part of the graph) by reducing the content of the
cysteinylated form (lower part of the graph). Legends to the symbol are reported in the figure.
In our experimental conditions the formation of HSA adducted by NAC was not detected at least
within the maximu incubation time of 120 in and this is in accordance with Harada who detected
the NAC adduct with HSA only after 6 hours of incubation [10] which is a quite extensive incubation
time considering that the T1/2 of N C corresponds to 3.97 hours after an oral intake. We selected a
maximum incubation time of 2 hours corresponding to the Tmax of NAC [23].
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The effect of NAC was time-dependent, reaching the maximum regenerating effect after 30 min of
incubation. As shown in Figure 3, the dose-dependent breaking effect was linear within a concentration
range of 25–100 µg/mL. The slope of 0.009 for the HSA-SH regeneration almost overlaps the slope of
−0.008 for HSA-Cys consumption, confirming the reaction (2).
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Figure 3. Regeneration effect of HSA-SH by NAC: Dose-dependent effect of NAC in regenerating
HSA-SH (positive slope) and in breaking (negative slope) the cysteinylated form.
According to the reaction constant as determined in the previous paragraph, the breaking effect of
Cys was more rapid, reaching the plateau of HSA-SH formation after only 5 min. As observed for
NAC, also in the case of Cys, a clear correlation between HSA-SH formation and HSA-Cys reduction
was observed. However, in contrast to what was observed for NAC, in the case of Cys we found
that immediately after the maximum recovery of HSA-SH, its relative content started to reduce in
parallel to the formation of the cysteinylated form. After almost 60 min of incubation the complete
recovery of HSA-SH was abolished and HSA-Cys reached the initial concentration. After this time
the cysteinylated form of HSA further increased with respect to the initial content, reaching at the
highest concentration a relative content of HSA-SH and HSA-Cys of 40.38% and 30.46% (with NAC:
100 µg/mL), respectively. Based on this data, it is clear that in the case of Cys, the dimer Cys-Cys rapidly
reacts with Cys34 forming again the mixed disulfide HSA-Cys. This behavior was not observed in
the presence of NAC since the relative content of Cys34 was maintained after reaching the maximum
amount of recovery, to indicate that the disulfide NAC-Cys is stable and does not react with Cys34 to
form the cysteinylated derivative.
To better understand the different reactivity of the disulfides Cys-Cys and NAC-Cys toward Cys34
a molecular modeling study was then carried out as reported in Section 3.4.
3.3. HSA-Cys Breaking Activity of NAC and Cys in Human Plasma from Healthy Donors
The next step was to confirm the HSA-Cys breaking activity of NAC in fresh human plasma
collected from healthy donors and characterized by a less content of cysteinylated albumin with respect
to that contained in the pool of plasma from Sigma. A concentration range of NAC (1–50 µg/ L) which
can be achieved after os or iv NAC treatment was used. Nolin et al. reported a Cmax (maximum
plasma concentration) of 2.5 µg/mL after a single 600 g oral dose which increases to 10 µg/mL in
end-stage renal disease patients and doubling to 20 µg/mL after a 1200 mg dose [23]. Plasma NAC
concentration after an Iv infusion ranges between 20 and 40 µg/ L as reported by Soldini et al. [24].
Figure 4 shows the dose-dependent effect of NAC in terms of HSA-SH regeneration and HSA-Cys
breaking activity after 60 min of incubation. The relative content of HSA-SH and HSA-Cys in absence
of NAC were 84% and 10% while the glycated form was around 5%. The breaking activity of NAC was
already observable at 1 µg/mL, to induce an almost complete recovery of HSA-SH and a concomitant
disappearance of HSA-Cys at 25 µg/mL.
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Figure 4. NAC regenerates HSA-SH in plasma of healthy donors: Dose-dependent effect of NAC in
re enerating HSA-SH (a) by breaking the cysteinylated form (b) in human lasma of healthy donors.
The breaking activity of NAC was then compared to that of Cys at a fixed dose of 25 µg/mL.
As shown in Figure 5, NAC was more effective in both restoring HSA-SH an in reducing HSA-Cy
and this is well xplained by the fact tha eve if Cys is more reactive, its efficacy is greatly reduced by
e reactivity of Cys-Cys disulfide with Cys34 that afte on hour of incub tion greatly reduced the
regenerating activity.
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Figure 5. Comparative analysis of NAC and Cys in breaking HSA-Cys (a) and restoring HSA-SH
(b). NAC and Cys were incubated with human plasma for 60 min at 37 ◦C. Significant differences are
indicated by * < 0.001 and ** p < 0.001; ANOVA test.
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3.4. Molecular Modeling Studies
With a view to explaining the different capacities of Cys and NAC to yield cysteinylated adducts,
the nucleophilic exchange between the possible disulfides (Cys-Cys and Cys-NAC) and Cys34
(represented by methanethiol for simplicity) to generate Cys-Cys34 and NAC-Cys34, respectively, were
simulated at gas phase and in water using the PCM method by density functional theory (DFT) using
the Becke three-parameter hybrid function with LYP correlation (DFT/B3LYP) and with the 6-31G
basis set as implemented by the GAMESS software [19]. For simplicity Cys34 was represented by a
methanethiol molecule which in fact corresponds to the side-chain of the cysteine. Such approximation
is justified by the clear impossibility to account for the protein environment by DFT calculations and on
the consideration that the reactivity of the thiolate moiety is unaffected by the Cys34 backbone atoms.
In detail, the simulations were focused on the formation of the key anionic trisulfide intermediates.
Figure 6 compares the two minimized intermediates and allows for some key observations. The first
consideration concerns the optimized distances between the sulfur atoms.
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Indeed, and while in the starting structures of both intermediates the three sulfur atoms were
placed so as to be equidistant, with the S-S distances equal to 2.2 Å, the optimized structures show
differences which are suggestive of their different reactivity. In detail, Figure 6, panel a shows that in the
trisulfide intermediate involving the Cys-Cys reactant, the S–S distance between Cys-S-S-Cys34 remains
at a distance comparable to the initial one (2.21 Å), while the Cys-S-S-Cys distance progressively
increases up to an optimized val e of 3.06 Å. Such a final structure is suggestive of a breaking of the
starting Cys-Cy d sulfide with he c rresponding exchange with Cys34. In contrast, the optimized
trisulfide intermediat involving the Cys-NAC rea tant (Figure 6, panel b) reveals an opposite situation
since the final Cys-S-S-NAC distance remains equal to 2.11 Å, while the Cys34-S-S-NAC distance
progressively increases up to an optimized value of 3.85 Å. The different behavior is also confirmed
by the angle values between the sulfur atoms (as defined by CH2-S . . . .S atoms). Indeed, while in the
Cys-Cys-C34 system all three angles assume values (around 100◦) which are suggestive of the observed
nucleophilic exchange, in the Cys-NAC-C34, the Cys 34 S atom approaches the S atom of NAC with an
unsuitable orientation (around 90◦) which confirms its incapacity to assume a pose conducive to the
exchange. The optimized structure depicted in Figure 6, panel b indicates therefore that the Cys-NAC
disulfide i unable to exchange with Cy 34. This diffe ent re ctivity fi ds compelling confirmation
in the relativ energies of the intermediates with respect to the isolated reactants as computed by
DFT calculations accounting for the water solvent by using the PCM approach. Indeed, the negative
relative energy of the intermediate involving the Cys-Cys disulfide is deep enough to allow for the
corresponding nucleophilic exchange, while the positive energy value for the intermediate with the
Cys-NAC disulfide clearly reveals that the corresponding exchange cannot occur.
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A second observation concerns the salt bridges characterizing the starting disulfides and the
corresponding intermediates. In detail, the Cys-Cys disulfide is a neutral zwitterionic molecule and
its structure is stabilized by two ion-pairs between the corresponding charged termini, while the
Cys-NAC disulfide is an anionic molecule, the structure of which involves only one ion-pair since
the carboxylated of the Cys residue remains uncoupled due to the acetyl group of NAC. Clearly, this
difference influences the approach of the anionic Cys34-S-moiety. Concerning the reaction involving
the Cys-Cys disulfide, Figure 6a shows that an ammonium head is addressed toward the sulfur atoms
favoring both the approach of Cys34-S- and the resulting exchange. By contrast, the negative charge
of the Cys-NAC disulfide prevents the approach of Cys34-S- and destabilizes the corresponding
intermediate due to simple electrostatic repulsion.
When simulating the formation of the trisulfide intermediates in gas phase, the difference between
the two relative energies markedly increases (∆E = −243.81 kJ/mol and ∆E = +120.46 kJ/mol) for the
intermediates involving Cys-Cys and Cys-NAC, respectively. This finding appears to be particularly
interesting for the nucleophilic exchange involving the Cys-Cys disulfide which appears greatly
favored when removing the solvent effect. On one hand, this result can be explained by considering
the shielding effect of water molecules on the ion-pairs promoting the reaction (see above), on the other
hand this suggests that such a nucleophilic exchange would occur more favorably when involving
cysteine residues embedded within rather hydrophobic environments as in the case of Cys34 which is
inserted into an apolar crevice.
3.5. Antioxidant Activity
The antioxidant activity was tested using the total peroxyl radical-trapping potential (TRAP) assay
that is based on a non-fluorescent substrate, which is oxidized to the fluorescent oxidation product by
the radical initiator AAPH which generates a constant flux of radical species. The antioxidant activity
is measured by calculating the lag-phase induced before the substrate oxidation [16,25].
Figure 7 shows the antioxidant activity of NAC and Cys (empty symbols) in a concentration range
of 25–100 µg/mL.
NAC was unable to induce a lag-phase even at the maximum dose used while a slight and
dose-dependent reduction of the rate of DCFH oxidation was observed indicating a slight antioxidant
activity but not enough to totally protect the substrate from the oxidation. In contrast, Cys induced a
dose-dependent lag-phase due to its greater direct antioxidant activity with respect to NAC, as expected.
The greater direct antioxidant of Cys with respect to NAC was then confirmed by using the ORAC
assay in which the antioxidant activity of NAC and Cys is compared to that of Trolox (Figure 8).
Human plasma induced a significant lag-phase which is the result of the combination of the several
plasma antioxidants including low molecular species, mainly uric acid, and proteins. Several papers
investigated the contribution of low and large molecules in plasma/serum to the total antioxidant
capacity. Wayner et al. first used the AAPH oxidation system to quantitatively evaluate the antioxidant
potential of human plasma and even if uric acid and vitamin E were identified as important players,
concluded that up to 73% of plasma antioxidant activity was associated with “protein and lipoprotein
material” [26].
More recently, Swertfeger et al. [27] using a proteomic and selective precipitation method,
identified the major antioxidant contributors able in preventing low-density lipoprotein (LDL) oxidative
modification, which is one factor thought to initiate and propagate plaque development, according to
the “oxidative modification hypothesis” [28]. The results indicated that ≈15% of activity is contributed
by fibrinogen, ≈20% by IgG, ≈1%–2% by HDL and ≈6% by small molecules, being albumin the
main antioxidant accounting for ≈40% of the antioxidant activity against water soluble radical and
copper-initiated oxidation mechanisms. Furthermore, it was reported that more than 70% of the free
radical-trapping activity of serum is due to HSA as assayed by the free radical-induced hemolysis
test [29]. These results indicate that HSA represents the major and predominant antioxidant in plasma
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whose relative contribution was reported to range from 40% to 70% of the total antioxidant capacity
of plasma.
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The antioxidant activity of albumin can be referred to Cys34 as well to the six methionine (Met)
residues and whose contribution was investigated using recombinant HSA mutants, in which Cys34
and/or the six Met residues had been mutated to Ala [30]. The results indicate that Cys34 plays the
most important role for the antioxidant activity of HSA against the tested oxidant species, namely
O2•−, •NO, HO•, HOCl, and H2O2.
Taking together, the data from the literature well indicate that HSA accounts from 40% to 70%
of the total antioxidant capacity of plasma which is mainly due to the presence of Cys34. As above
discussed, when Cys34 acts as antioxidant, it is converted to the cysteinylated form to prevent a
further oxidation to the irreversible forms. In the cysteinylated form, Cys34 is clearly not effective as
antioxidant, making the ability of NAC to selectively restore Cys34 a potential mechanism of restoring
the antioxidant capacity of plasma in oxidative stress conditions.
To demonstrate this important mechanism, human plasma was incubated with NAC and then
oxidized by the radical initiator. As shown in Figure 7, NAC dose-dependently increased the plasma
antioxidant activity. Figure 9 shows the relationship between dose and lag-phase for NAC in absence
and presence of plasma. The lag-phase induced by plasma accounted for almost 100 min which
increased by NAC spiking by 27%, 45%, and 60% at the doses of 25, 50 and 100 µg/mL, respectively.
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Figure 9. Dose-dependent lag-phase induced by NAC (a) and Cys (b) in absence and presence
of plasma.
It should be underlined that NAC alone, at the same doses, was found unable to induce the
lag-phase (Figures 8 and 9) thus demonstrating that the effect of NAC in plasma is not due to a direct
effect but rather to an indirect effect mechanism mediated by the Cys34 regeneration. Although Cys as
such dose-dependently increased the lag-phase, when it was spiked to plasma it did not significantly
increased the lag-phase (Figures 8 and 9). This effect is explained by considering the kinetic as reported
in Section 3.2. In particular, during the incubation of Cys with plasma, it rapidly breaks the disulfide
bond and free Cys34 but then the reverse reaction mediated by Cys-Cys (also formed by the oxidation
of Cys in plasma) reforms the cysteinylated form of Cys34 thus neutralizing the antioxidant effect.
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3.6. NAC Is an Indirect Antioxidant at Extracellular Level: The Role of Cys34
The overall data well indicates that NAC is able to restore the antioxidant activity of plasma even
if the reaction constants of NAC toward the most reactive oxidizing species do not make NAC a direct
scavenger. The mechanism is summarized in Figure 10 where Cys34 of albumin acts with a pivotal
role in the antioxidant activity of plasma.
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Figure 10. Indirect antioxidant mechanism of NAC at extracellular level - Cys34 of mercaptoalbumin
(HSA-SH) efficiently scavenges oxidant species forming the corresponding sulfenic acid which then
reacts with Cys to form th cysteinyl ted adduct (HSA-Cys). NAC is able to s lectively break
disulfide bond of HSA-Cys l ading the disulfi e NAC-Cys and the free form of Cys34 which in turn
further acts as antioxidant.
When Cys34 scavenges the oxidant species, the corresponding sulfenic acid is formed which then
reacts with Cys to form the cysteinylated adduct. NAC is able to selectively break the disulfide bond
leading the disulfide NAC-Cys and the free form of Cys34 which in turn further acts as antioxidant. In
contrast to other disulfides, such as Cys-Cys, NAC-Cys does not react back with Cys34 as demonstrated
by molecular modeling studies, thus maintaining the Cys34 in a free form, making NAC a suitable
thiol-disulfide breaking compound.
4. Conclusions
In onclusion, the present paper demonstrates that NAC enhances the plasma antioxidant activity
by restoring Cys34 through a selective thiol-disulfide mechanism. The ability of NAC to restore Cys34
in patients with oxidative-based diseases and characterized by an impaired balance between Cys34 in
free and disulfide form is currently under investigation by us. By considering the role of oxidative
stress and in particular of plasma oxidation in several diseases, the availability of a drug able to
regenerate the endogenous defense is of great value and its application to chronic diseases, where
oxidative stress plays an important role, should be carefully evaluated. Finally, it should be considered
that NAC restores albumin Cys34 which is an endogenous protein with a half-time of three weeks and
hence the antioxidant activity of NAC is not strictly related to its residence time (short due to its rapid
clearance) as it would be in the case of a direct exogenous antioxidant.
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